The Acuitas Advantage
Our unique advantage is the combination of our best-in-class lipid nanoparticle (LNP) delivery technology with a collaborative business model that accelerates and de-risks the advancement of partner products into clinical development. We do not develop our own drug products; instead, our total focus is supporting our partners through the entire drug development process using our validated LNP technology. Our partners know that our objectives and priorities are entirely aligned with theirs.
Best-in-class & First-in-class
Our LNP technology is clinically validated. We are proud of the success of ONPATTRO®, the first FDA-approved RNA interference therapeutic. This lifesaving drug is now available globally to those afflicted with transthyretin amyloidosis. Acuitas’ LNP technology also enables the COVID-19 vaccine COMIRNATY®, which has protected billions of people in more than 180 countries worldwide.
We Accelerate Our Partners’ Clinical Entry
Our familiarity with all aspects of the drug development process allows us to anticipate our partners’ needs, providing support and expertise from preclinical development to regulatory approval and commercial manufacturing. Understanding the importance of rapid clinical entry, we ensure efficient technology transfer and access to cGMP-grade proprietary lipids. In addition, our expertise in clinical translation and manufacturing scale-up de-risks the overall development process for our partners – saving them time and money.
Broad Intellectual Property Portfolio
Our groundbreaking technology is strongly protected by a broad global IP portfolio. Licenses to our partners enable them to not only utilize our technology to develop successful products but also fend off generic competition. While our ongoing focus is robust composition of matter patents covering our novel lipids and LNP formulations, we also file patents covering treatment methods, lab and clinical techniques and biological mechanisms of action, further empowering our partners to develop best-in-class medicines.
Unparalleled Scientific Leadership & Experience
We work with academic researchers and key opinion leaders, regularly publishing in the highest impact scientific journals. At the cutting edge of scientific discovery, our team is contributing to the latest developments in nucleic acid therapeutics.
Working with Acuitas, our partners have initiated 26 clinical trials in 2023/2024. We know what is required for clinical translation and the best strategies to get there.
Our Business Model
The Acuitas business model is unique: Our full commitment is to our partners and accelerating their path to the clinic and the market, as we do not engage in therapeutic development on our own. Discover the benefits of partnering with us.
Our technology.
Our best-in-class in LNP delivery technology enables new classes of medicines based on biological molecules (nucleic acids).
The benefits of partnering with us.
The Acuitas team is committed to supporting our partners and accelerating their path to the clinic and the market. Discover the benefits of partnering with Acuitas.